Fidelity Investments Variable Annuity Account I has made a significant update regarding the current expenses for its Fidelity VIP Freedom Lifetime Income Portfolios. This change, effective November 1, 2026, is crucial for existing and potential policyholders as it reflects Fidelity's ongoing efforts to adapt to market conditions and enhance the value of its offerings.
Fidelity Investments Variable Annuity Account I, incorporated in Utah, operates as an investment entity. The company is primarily focused on providing variable annuity products, which are designed to offer policyholders a combination of insurance and investment options. Fidelity has consistently filed various forms with the SEC, including recent filings on October 30, 2026, which detail updates to their prospectus and expenses.
The recent filing, dated October 30, 2026, outlines the changes to the current expenses associated with the Fidelity VIP Freedom Lifetime Income Portfolios. According to the filing, "Effective November 1, 2026, current expenses for the Fidelity VIP Freedom Lifetime Income Portfolios have changed." This update is part of Fidelity's broader strategy to ensure that its products remain competitive and attractive to investors.
This update may impact existing policyholders who are invested in the Fidelity VIP Freedom Lifetime Income Portfolios. It also signals to potential investors that Fidelity is actively managing its offerings to align with market trends and customer needs. The changes may also influence the competitive landscape among other investment firms that offer similar variable annuity products.
Looking ahead, Fidelity is likely to continue monitoring the performance of its portfolios and may provide further updates in future filings. The filing does not specify what additional actions may follow this update, leaving room for speculation on future adjustments to their investment strategies.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






